1. Home
  2. IPO
  • Medistep Healthcare Ltd IPO
star-imaging

Medistep Healthcare IPO

  • Status: Closed
  • RHP:
  • ₹ 258,000 / 6000 shares

    Minimum Investment

IPO Listing Details

  • Listing Date

    18 Aug 2025

  • Listing Price

    ₹ 53.00

  • Listing Change

    23.26%

  • Last Traded Price

    ₹ 25.00

Medistep Healthcare IPO Details

  • Open Date

    08 Aug 2025

  • Close Date

    12 Aug 2025

  • Listing Date

    18 Aug 2025

  • IPO Price Range

    ₹ 43

  • IPO Size

    ₹ 15.29 Cr

  • Listing Exchange

    NSE SME

Open Free Demat Account

+91
Resend OTP

By proceeding, you agree to all T&C*

hero_form
Timeline Subscription Status Financials SWOT FAQ Contacts

Medistep Healthcare IPO Timeline

Medistep Healthcare IPO Subscription Status

Last Updated: 12 August 2025 6:28 PM by 5paisa

Medistep Healthcare Limited is launching a ₹15.29 crore IPO. The company manufactures a wide range of products including sanitary pads, energy powders, and pharmaceutical, nutraceutical, intimate hygiene, and surgical items. With a focus on quality and wellness, Medistep aims to expand its presence in the healthcare sector. The company operates as a public, non-government entity and is poised to strengthen its offerings through this public issue.

Established in: 2023
Managing Director: Girdhari Lal Prajapat

Peers
Fabino Enterprises Limited
Achyut Healthcare Limited

Medistep Healthcare Objectives

1. The funds will be used to purchase plant and machinery for expansion at the existing manufacturing facility.
2. A portion of the proceeds will be allocated to meet working capital requirements.
3. The remaining funds will be utilised for general corporate purposes.
 

Medistep Healthcare IPO Size

Types Size
Total IPO Size ₹15.29 Cr
Offer For Sale -
Fresh Issue ₹15.29Cr

Medistep Healthcare IPO Lot Size

Application Lots Shares Amount
Retail (Min) 2 6,000 ₹258,000
Retail (Max) 2 6,000 ₹258,000
HNI (Min) 3 9,000 ₹387,000

Medistep Healthcare IPO Reservation

Investors Category Subscription (times) Shares Offered Shares bid for Total Amount (Cr.)*
QIB 0.00 0.00 0.00 0.00
NII (HNI) 60.46 17,76,000 10,73,82,000 461.74
Retail 190.28 17,79,000 33,85,02,000 1,455.56
Total** 125.47 35,55,000 44,60,40,000 1,917.97

 

*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.

Profit and Loss

Balance Sheet

Particulars (in Rs. Crores) FY23 FY24 FY25
Revenue 27.65 39.07 49.65
EBITDA 1.34 3.96 5.60
PAT 0.92 3.33 4.14
Particulars (in Rs. Crores) FY23 FY24 FY25
Total Assets 14.66 14.96 22.99
Share Capital 1.07 6.32 10.47
Total Borrowings 0.53 0.33 0.64
Particulars (in Rs. Crores) FY23 FY24 FY25
Net Cash Generated From / (used in) operating activities 0.44 -6.96 0.02
Net Cash Generated From / (used in) investing activities - -0.15 -
Net Cash Generated From / (used in) financing activities -0.35 7.00 1.28
Net Increase (Decrease) In Cash And Cash Equivalents 0.09 -0.11 1.30


Strengths

1. Wide distribution network across retail and wholesale channels.
2. Low-cost products cater to mass market demand.
3. Diverse product range in pharma, nutraceuticals, and hygiene.
4. Experienced promoters and efficient management team.
 

Weaknesses

1. Limited brand visibility in a competitive market.
2. Heavy reliance on raw material suppliers.
3. Faces operational risks due to supply chain issues.
4. Brand still building consumer trust and loyalty.

Opportunities

1. Rising awareness of women's health and hygiene.
2. Potential tie-ups with NGOs and health organisations.
3. Growing demand for affordable healthcare products.
4. Expanding product lines to new regional markets.
 

Threats

1. Fierce competition from larger, well-known brands.
2. Volatility in raw material and input costs.
3. Shifts in consumer preference and buying behaviour.
4. Regulatory changes affecting pharma and health sectors.

1. Consistent revenue and PAT growth from FY23 to FY25 indicates solid financial performance.
2. Operates in fast-growing healthcare, hygiene, and nutraceutical segments with rising national demand.
3. IPO proceeds support boosting capacity and operational scale at existing facility.
4. Backed by experienced promoters with a diverse product portfolio across essential health categories.
 

1. India’s feminine hygiene market is projected to reach USD 3.08 billion by 2030.
2. Rising awareness, urbanisation, and online retail are driving demand for hygiene and wellness products.
3. India’s pharmaceutical market is expected to grow from USD 50 billion to USD 130 billion by 2030.
4. Demand for eco-friendly and organic products is creating new opportunities in healthcare and hygiene.
 

Upcoming IPOs

View all IPOs
  • Companies
  • Type
  • Opening On

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
Resend OTP

By proceeding, you agree to all T&C*

footer_form

FAQs

Medistep Healthcare IPO opens from August 8, 2025 to August 12, 2025.

The size of Medistep Healthcare IPO is ₹15.29 Cr.

The price band of Medistep Healthcare IPO is ₹43 per share. 

1. To apply for Medistep Healthcare IPO, follow the steps given below:
2. Login to your 5paisa account and select the issue in the current IPO section.    
3. Enter the number of lots and the price at which you wish to apply for the Medistep Healthcare IPO. 
4. Enter your UPI ID and click on submit. You will receive a mandate notification to block funds in your UPI app.
5. On approving the mandate, your bid will be placed with the exchange.   

The minimum lot size of Medistep Healthcare IPO is 2 lots of 6,000 shares and the investment required is ₹258,000.

The share allotment date of Medistep Healthcare IPO is August 13, 2025

The Medistep Healthcare IPO will likely be listed on August 18, 2025.
 

Fast Track Finsec Pvt Ltd is the book running lead manager for Medistep Healthcare IPO.

1. The funds will be used to purchase plant and machinery for expansion at the existing manufacturing facility.
2. A portion of the proceeds will be allocated to meet working capital requirements.
3. The remaining funds will be utilised for general corporate purposes.